Cardiovascular disease (CVD) is a prevalent condition in the elderly, often associated with metabolic disturbance and type 2 diabetes. For a number of years, research dedicated to understand atherosclerosis dominated, and for many good reasons, this pathophysiological process being proximal to the CVD events. In recent years, research has been devoted to an earlier stage of vascular pathology named arteriosclerosis (arterial stiffness) and the new concept of early vascular ageing (EVA), developed by a group of mostly European researchers.
Thomas Sydenham, the great English seventeenth-century physician (see Figure 1) , said that "A man is as old as his arteries", a concept that has once again come into focus of cardiovascular research and clinical activities, which this review aims to describe.
In preventive cardiology there has long existed the need to target individuals at risk for preventive action based on lifestyle improvement and intervention related to conventional risk factors for cardiovascular disease (CVD) manifestations (hyperlipidaemia, hypertension, smoking, diabetes). This has been made possible by use of specific risk algorithms based on follow-up investigations of screened subjects for prediction of events in large population-based cohorts. Famous examples include the Framingham Risk Score (FRS) 1 and the European SCORE, which originated with the Danish algorithm PRECARD, 2 as well as other lessknown algorithms (PROCAM from Germany; Q-RISK from the UK). The SCORE system has been calibrated to national applications based on national cardiovascular statistics on CVD endpoints. Computer applications have been widely distributed, even when the clinical uptake is difficult to quantify.
At least the US-based FRS has been found to overestimate the cardiovascular risk in many European populations, providing a reason for using SCORE instead. 3, 4 Furthermore, new versions of SCORE, including high-density lipoprotein (HDL) cholesterol and not only total cholesterol, will reclassify patients more correctly for risk categories than does the traditional SCORE. 5 For cardiovascular complications of type 2 diabetes, some other risk algorithms have been developed in newly detected patients, based mostly on the UK Prospective Diabetes Study (UKPDS) Risk Engine, 6 but also based on national register data on treated patients with type 2 diabetes from Sweden. 7 The endpoint most commonly used for these algorithms was cardiovascular events (fatal or non-fatal), generally caused by atherosclerosis, plaque rupture or thrombo-embolic mechanisms. In more recent years, the research activities dedicated to atherosclerosis also started to involve effects of acute or chronic inflammation mediating the risk of CVD -for example, in patients with the metabolic syndrome. 8 Inflammation is often linked to abdominal obesity, insulin resistance and hepatic steathosis and supposed to be both general and local -that is, perivascular by As every human being has once been pre-formed in utero, some hypotheses hold that early life influences could play a role in development of arterial function and vascular morphology, leading to increased risk of arteriosclerosis as visible at least in young adulthood.
All components of the vascular tree may be affected -for example, the elastin content and thinness of the arterial wall; the development of the microcirculation, as can be studied in the retinal bed; and, finally, the number and functionality of capillaries.
The famous mismatch hypothesis denotes the detrimental effects of intrauterine growth retardation (IUGR) in combination with post-natal catch-up growth patterns for increased risk of CVD and type 2 diabetes in adulthood. 13 Because these changes are also related to ageing, it has been proposed that a process of EVA is an early sign of arteriosclerosis (in the media) but is linked also to early changes in the endothelial function (intima), to haemodynamic changes and to the influence of abnormal glucose metabolism and increased inflammation, as reviewed. 14, 15 The links with type 2 diabetes are shown in Table 1 .
The difference between the concept of arterial ageing and EVA is that the latter also encompasses changes in the smaller arteriolae and the microcirculation based on the cross-talk between the macro-and micro-circulation as evident in the origin of vascular brain damage. of impaired renal function. 18 Our own interpretation is thus that two different clusters of CVD risk factors could be shown and that these are, relatively speaking, differently involved along the life course for development, first, of arteriosclerosis and, later on, of atherosclerosis, starting in young adulthood and mid-life. Finally, in elderly subjects, there may exist a merged phenotype of combined arterio-and atherosclerosis close to clinical events and symptomatic coronary heart disease or CVD, as well as peripheral artery disease.
In the MDC study, levels of arterial stiffness were also higher in subjects having known or newly detected diabetes compared with subjects without diabetes (see Figure 2 ). In another set of analyses from the same cohort, it was shown that arterial stiffness (c-f PWV), at least at the higher end of the distribution, is associated with impaired cognitive function as measured in a cross-sectional analysis, especially concerning so-called speed and executive testing, but not with traditional memory tests such as Mini-Mental State Examination (MMSE). 19 Vascular ageing thus links to brain and cognitive ageing.
Genetic Factors Associated with Arterial Stiffness
Attempts have been made to think about how to define EVA by taking into account background factors such as age, sex and ethnicity, but what can we learn from genetics? There is now a list of about 40 genetic markers of hypertension 20 that in a joint Italian-American study did not seem to overlap with other genetic markers associated with arterial stiffness. 21 Still more work has to be done to understand the genetic 
Telomere Length and Vascular Ageing -A Methodological Challenge
The role of telomere length in relation to arterial stiffness and vascular ageing is still not well understood, and even if telomere length is regarded as a marker of biological ageing, it has not been uniformly associated with vascular ageing -for example, in the Belgian Asklepios study based on cross-sectional data in largely healthy individuals. 23 The methodological solution to this could be to use repeated measurements of telomere length during follow-up to calculate the so-called telomere attrition rate, which could be a better marker of ageing than cross-sectional measures alone. In addition, the analyses of other aspects of telomere biology, such as telomerase function and telomere binding proteins, could contribute to deeper understanding than telomere length itself.
Prediction of Cardiovascular Disease Based on Arterial Stiffness
Increased c-f PWV as a marker of arterial stiffness is an independent risk marker for cardiovascular events and total mortality, even adjusted for traditional risk factors, and even more so in the middle-aged compared with the elderly. 24 This age-linked influence could mean that differential ageing in general, and vascular ageing in particular, is more visible in middle-aged subjects than in the elderly, among whom also selective survival bias could play a role. Two consensus papers have been published: one from 2006 on methods to evaluate c-f PWV; 25 one from 2012 on a defined risk threshold of 10 m/s for c-f PWV, 26 reflecting arterial stiffness and a recommendation for standardisation of measurement.
The statement is that the crucial length component should be calculated by direct measurement of the distance between the carotid and the femoral arteries but multi-plicated with 0.8. 26 The travelled distance of the pulse wave may be shorter than the one calculated by external Another important factor is impaired glucose metabolism and hyperglycaemia with effect on the properties of the arterial wall arising from glycation of vessel wall proteins, but also changes of other functions, such as innervation, vascularisation of the arterial wall (via vasa vasorum) and changes in the perivascular fat with inflammation. In pre-diabetes or subjects who have the metabolic syndrome, as well as in established diabetes, these changes can be seen, as described. 31 Prenner et al.
even state that some data suggest that arterial stiffness can predict the onset of diabetes. 32 However, more research is needed to understand whether large artery stiffness and the pulsatile haemodynamic changes that accompany it are involved in the pathogenesis of diabetes. An even more intriguing question is how interventions targeting arterial stiffness could be used to improve clinical outcomes in diabetes.
A specific feature of the arterial wall in patients who have end-stage renal disease (ESRD) is vascular calcification of the media. This is different from conventional atherosclerosis of the intima but can contribute to aortic stiffness. 33 It is still an open question whether this process starts earlier in the course of chronic kidney disease (CKD)-in fact so early that conventional imaging will not be able to detect it, but rather only specific imaging for metabolic processes. There is no doubt that a close link exists between CKD and CVD as well as with metabolic changesfor example, secondary hypercholesterolaemia -or that the degree of albuminuria is an easy-to-quantify marker of this increased risk.
Obesity and Arterial Stiffness
It is well known that obese children and adolescents, even young adults, tend to have a phenotype of hyperkinetic circulation and vasodilation -the opposite to arterial stiffness -but also a relative endothelial dysfunction.
This could lead to increasing blood pressure levels, remodelling of small arteries and, later on, an increase in peripheral vascular resistance and blood pressure, leading to overt hypertension when arterial stiffness is also a gradually increasing feature. The exact regulation of the transition from relative vasodilation in the young obese subject to arterial stiffness in adults is not known, but genetic factors, arterial structure, endothelial dysfunction with impaired nitric oxide (NO) production and the time factor itself could contribute to these changes.
Results from a prospective study showed that central obesity predicts arterial stiffness over a period of 16 years, 34 whereas a follow-up study 20 years later, including men, indicates that heavy smoking, C-reactive protein (CRP) and pulse pressure (PP) are predictors of arterial stiffness.
These data reinforce the importance of chronic inflammation for the development of EVA, as already discussed. However, no study data are available to show cardiovascular benefits by specific target or to treat chronic inflammation. On the other hand, the use of non-steroidal anti-inflammatory agents (NSAIDs) has been associated with increased CVD risk, in particular congestive heart failure. Thus the role of chronic inflammation as a target for the treatment strategy is still elusive.
Gene-Environment Interaction in Cardiometabolic Risk
The family background of many chronic disease conditions is well known and is often asked after during the clinical consultation.
There are examples of families at high cardiometabolic risk, and in one register-based study, a special mother-son CVD risk association was described. 35 The family connection has been documented in several epidemiological studies and also brought into focus based on genetic studies. One conceptual problem to understand is the limited power of combined genetic risk scores (GRS) to explain more than a tiny proportion of this family-associated disease risk. This is why researchers have now tried to define the so-called missing heritability (non-GRS-mediated) believed to involve the influence of gene-environment interactions (epigenetics), lifestyle, early life programming and even the role played by gut microbiota, with its high degree of family resemblance. 36 In fact, the role of microbiota for risk of cardiometabolic disease is emerging, and even if links have been shown with atherosclerosis, 37 still no studies have reported on the association between gut microbiota patterns and arterial stiffness. 
Multiple Cardiovascular Risk Factor Control for Early Vascular Ageing
As increased c-f PWV has been documented as an independent risk marker for future cardiovascular events and total mortality in a recent meta-analysis, 24 there is a need to target it with multiple risk factor control, aiming for c-f PWV <10 m/s that is the current threshold for increased risk. 26 Still, however, no specific treatments exist to target arterial stiffness itself, and no randomised trial is known to have One animal experiment reported that C21 could prevent vascular dementia. 50 If these intervention effects can also be repeated in humans and with a positive tolerance profile, the drug could be used for vascular protection in combination with more conventional antihypertensive and lipid-lowering drugs. So far, the safety profile seems to be beneficial in the animal experiments, even at supranormal dosages of C21.
Another way to treat arterial stiffness is to try the effect of transcutaneous electrical nerve stimulation (TENS). This physical intervention applied on the skin has been evaluated in a randomised, controlled study in Time will tell. n
